MERRIMACK PHARMACEUTICALS IN (MACK)

Merrimack Receives $225 Million Milestone Payment from Ipsen

MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023

Merrimack Pharmaceuticals just reported results for the fourth quarter of 2023.

Merrimack Reports Full Year 2023 Financial Results

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Friday 12/29 Insider Buying Report: MACK, EWTX

Friday 11/17 Insider Buying Report: MACK, DAR

Merrimack Reports Third Quarter 2023 Financial Results

Pancreatic Cancer Battle Boosted by $200M VC Firm

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

Pancreatic Cancer Battle Boosted by $200M VC Firm

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

Thursday 8/10 Insider Buying Report: CVBF, MACK

Merrimack Reports Second Quarter 2023 Financial Results

RSI Alert: Merrimack Pharmaceuticals (MACK) Now Oversold

Merrimack Reports First Quarter 2023 Financial Results

Thursday 3/23 Insider Buying Report: MACK, ONEW

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning!

Merrimack Reports Full Year 2022 Financial Results

Tuesday 1/10 Insider Buying Report: MACK, CZNC

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is still reaping the drug’s benefit despite being a shuttered […]

Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...

Upstart (UPST) Stock Sinks on Gloomy Forecast

Upstart (UPST) stock is sliding lower on Wednesday following a poor performance in the third quarter of 2022 and a weak outlook.

Why Is Merrimack Pharmaceuticals (MACK) Stock Up 220% Today?

Merrimack Pharmaceuticals (MACK) stock is rocketing higher on Wednesday following positive Phase III clinical trial data.